Renaissance Capital logo

Zosano Pharma Priced, Nasdaq: ZSAN

Developing a transdermal formulation of an approved osteoporosis treatment.

Industry: Health Care

First Day Return: +0.1%

Industry: Health Care

We are a clinical stage specialty pharmaceutical company that has developed a proprietary transdermal microneedle patch system to deliver our proprietary formulations of existing drugs through the skin for the treatment of a variety of indications. Our microneedle patch system offers rapid onset, consistent drug delivery, improved ease of use and room-temperature stability, benefits that we believe often are unavailable using oral formulations or injections. Our microneedle patch system has the potential to deliver numerous medications for a wide variety of indications in commercially attractive markets. By focusing our development efforts on the delivery of established molecules with known safety and efficacy and premium pricing, we plan to reduce our clinical and regulatory risk and development costs and accelerate our time to commercialization.
more less
IPO Data
IPO File Date 06/24/2014
Offer Price $11.00
Price Range $10.00 - $12.00
Offer Shares (mm) 4.5
Deal Size ($mm) $50
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 01/26/2015
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $50
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters Fremont, CA, United States
Founded 2007
Employees at IPO 29
Website www.zosanopharma.com

Zosano Pharma (ZSAN) Performance